NCT02334865View on ClinicalTrials.gov

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 13, 2017

Primary Completion Date

September 16, 2022

Study Completion Date

May 19, 2026

Conditions
Partial Response of Multiple Myeloma or Plasma Cell LeukemiaPlasma Cell Myeloma
Interventions
BIOLOGICAL

Incomplete Freund's Adjuvant

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

BIOLOGICAL

Sargramostim

Given SC

BIOLOGICAL

SVN53-67/M57-KLH Peptide Vaccine

Given SC

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

14642

University of Rochester Medical Center, Rochester

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER